Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind comparison of CVT-3146 (regadenoson) vs Adenoscan in stress myocardial perfusion imaging
2004-004976-35Phase 3Completed
- Sponsor
- CV Therapeutics, Inc.
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of regadenoson in cardiac ischemia (2 arms), sponsored by CV Therapeutics, Inc. Primary endpoint: Primary agreement between CVT-3146 and adenosine SPECT images. Started Jul 2005; status: completed.
02
Drugs
regadenoson
03
Conditions
cardiac ischemia
Beyond the preview
Go deeper on 2004-004976-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004976-35.